AGC
RNAM

Angelo Gordon & Co’s Avidity Biosciences RNAM Stock Holding History

Angelo Gordon & Co’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$3.25M Buy
+45,000
New +$2.91M 0.31% 38

Other funds holding RNAM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Angelo Gordon & Co's RNAM Position: Q4 2025 in Review

Angelo Gordon & Co opened a new position in Avidity Biosciences (RNAM) in Q4 2025: 45,000 shares worth $3.25M. The stake represents 0.31% of the portfolio and ranks #38 among its holdings.

343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

  • Angelo Gordon & Co held 45,000 shares of Avidity Biosciences worth $3.25M as of Q4 2025.
  • Avidity Biosciences was a new Angelo Gordon & Co position in Q4 2025.
  • Avidity Biosciences made up 0.31% of Angelo Gordon & Co's portfolio in Q4 2025, its #38 holding.
  • 343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on Angelo Gordon & Co's 13F filing for Q4 2025, filed 17 Feb 2026.